IND Readiness Platform Pii launched the Accelevate Early Development Platform in October 2024 to accelerate IND readiness for aseptic products, targeting small to mid-sized biopharma and accelerating the path to clinic within about 100 days.

PFS Expansion A 2024 financing of 3.6 million dollars expanded prefilled syringe capabilities, including advanced labeling, fill/finish, and automated visual inspection, enabling streamlined packaging for costly biologics and specialty drugs.

Aseptic High Potency Pii specializes in aseptic filling, lyophilization, and high potency isolation, with experience handling potent compounds and controlled substances, offering a one-stop option for biotech and niche pharma needing complex formulations at small-to-mid volumes.

Acquisition Advantage The February 2025 acquisition by Jabil provides access to a broader engineering, manufacturing, and supply-chain ecosystem, creating potential cross-sell opportunities to Jabil's large customer base and integrated services for end-to-end manufacturing.

Security Opportunity A December 2025 data breach affecting PII highlights the growing importance of data protection and regulatory compliance; this creates a sales angle to offer or coordinate robust data-security and privacy services for Pii and its clients as part of a CDMO engagement.